angliz personal page - To The Moon

angliz

angliz

No personal profile

430Follow

95Followers

0Topic

0Badge

2022-06-07

Go go go!

Some Hot Chinese ADRs Gained in Morning Trading

2022-06-04

$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Just bought abit of this share today! Huat ah!

2022-01-28

Wowed

Apple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst

2022-01-21

Horray!

Hot Chinese ADRs Gained in Morning Trading

2022-01-12

🥳

Why Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today

2022-01-09

How many doses do we have to take eventually?🤪

3 COVID Stocks That Will Make Billions in 2022

2021-09-23

$CapitaLandInves(9CI.SI)$Went up for the past few days

2021-09-23

$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$CGS-CIMB keeps 'add' on ThaiBev on attractive valuation.Link below:https://www.theedgesingapore.com/capital/brokers-calls/cgs-cimb-keeps-add-thaibev-attractive-valuation

2021-09-22

$HONG LEONG ASIA LTD.(H22.SI)$I am expecting this share to be around $1.

2021-09-22

$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Be patience.

2021-09-21

$Baidu(BIDU)$share my position

2021-09-21

$ESR-REIT(J91U.SI)$share my position

2021-09-20

$Pfizer(PFE)$Will you get this stock?

2021-09-16

$HONG LEONG ASIA LTD.(H22.SI)$When is your show time to have the upward trend?

2021-09-14

$Baidu(BIDU)$Share my position.

2021-09-14

$SEMBCORP INDUSTRIES LTD(U96.SI)$Will you buy this share with loss PE? This share is meant for long term.

2021-09-13

$CHINA EVERBRIGHT WATER LIMITED(U9E.SI)$what happened to this stock?

2021-09-13

$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Hope to see you in green again.

2021-09-10

$Baidu(BIDU)$AI is the next IOT. Please support this stock.

2021-09-10

$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$share my position

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581117504935343","uuid":"3581117504935343","gmtCreate":1618148430364,"gmtModify":1706620740447,"name":"angliz","pinyin":"angliz","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":95,"headSize":430,"tweetSize":179,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9051023287,"gmtCreate":1654611383749,"gmtModify":1676535477923,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"Go go go!","listText":"Go go go!","text":"Go go go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9051023287","repostId":"1128523151","repostType":2,"repost":{"id":"1128523151","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1654609740,"share":"https://ttm.financial/m/news/1128523151?lang=&edition=fundamental","pubTime":"2022-06-07 21:49","market":"us","language":"en","title":"Some Hot Chinese ADRs Gained in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1128523151","media":"Tiger Newspress","summary":"Some Hot Chinese ADRs Gained in Morning Trading.Alibaba, Pinduoduo, iQIYI, DiDi Global, Baidu, JD.co","content":"<html><head></head><body><p>Some Hot Chinese ADRs Gained in Morning Trading.</p><p><a href=\"https://laohu8.com/S/BABA\">Alibaba</a>, <a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>, iQIYI, DiDi Global, <a href=\"https://laohu8.com/S/BIDU\">Baidu</a>, <a href=\"https://laohu8.com/S/JD\">JD.com</a>, Bilibili, and NIO climbed between 1% and 7%.</p><p><img src=\"https://static.tigerbbs.com/46cf305cfd9d3f235469219b4a219ad7\" tg-width=\"445\" tg-height=\"647\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Hot Chinese ADRs Gained in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Hot Chinese ADRs Gained in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-06-07 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some Hot Chinese ADRs Gained in Morning Trading.</p><p><a href=\"https://laohu8.com/S/BABA\">Alibaba</a>, <a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>, iQIYI, DiDi Global, <a href=\"https://laohu8.com/S/BIDU\">Baidu</a>, <a href=\"https://laohu8.com/S/JD\">JD.com</a>, Bilibili, and NIO climbed between 1% and 7%.</p><p><img src=\"https://static.tigerbbs.com/46cf305cfd9d3f235469219b4a219ad7\" tg-width=\"445\" tg-height=\"647\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","PDD":"拼多多","BILI":"哔哩哔哩","BIDU":"百度","BK4577":"网络游戏","BK4579":"人工智能","BK4552":"Archegos爆仓风波概念","BK4122":"互联网与直销零售","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4502":"阿里概念","BK1521":"挪威政府全球养老基金持仓","BK4510":"在线教育","BK1586":"云计算","BK1095":"互动媒体与服务","09888":"百度集团-SW","BK1142":"互联网与直销零售","BK1591":"就地过年概念","09988":"阿里巴巴-W","09618":"京东集团-SW","JD":"京东"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128523151","content_text":"Some Hot Chinese ADRs Gained in Morning Trading.Alibaba, Pinduoduo, iQIYI, DiDi Global, Baidu, JD.com, Bilibili, and NIO climbed between 1% and 7%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9059990241,"gmtCreate":1654272962983,"gmtModify":1676535423684,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Just bought abit of this share today! Huat ah!","listText":"<a href=\"https://ttm.financial/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Just bought abit of this share today! Huat ah!","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Just bought abit of this share today! Huat ah!","images":[{"img":"https://community-static.tradeup.com/news/be2d3c77e2bf92d52c4e7bdab6f2bafe","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9059990241","isVote":1,"tweetType":1,"viewCount":342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9099849467,"gmtCreate":1643334461026,"gmtModify":1676533806783,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"Wowed","listText":"Wowed","text":"Wowed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9099849467","repostId":"1110430857","repostType":4,"repost":{"id":"1110430857","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1643329098,"share":"https://ttm.financial/m/news/1110430857?lang=&edition=fundamental","pubTime":"2022-01-28 08:18","market":"us","language":"en","title":"Apple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1110430857","media":"Benzinga","summary":"Apple, Inc. reported late Thursday with strong quarterly results that \"wowed\" a Wedbush analyst.The ","content":"<html><head></head><body><p><b>Apple, Inc.</b> reported late Thursday with strong quarterly results that &#34;wowed&#34; a Wedbush analyst.</p><p><img src=\"https://static.tigerbbs.com/46f1d5c88a1b989ac1e46cf46560b032\" tg-width=\"660\" tg-height=\"300\" width=\"100%\" height=\"auto\"/></p><p><b>The Apple Analyst:</b>Daniel Ives has an Outperform rating on Apple with a $200 price target.</p><p><b>The Apple Takeaways:</b>Apple&#39;s robust quarter will be the focus of the tech universe, especially as the Street harbored major supply chain and growth fears, heading into the print, Ives said in a note.</p><p>The iPhone was the &#34;star of the show,&#34; as revenues from the product beat the Street estimates and the Services business also exceeded expectations, the analyst said. The beat was across all product categories, except the iPad, he said.</p><p>The bottom-line result of $2.10 and margins were also ahead of expectations, Ives said.</p><p>&#34;Overall, with $6 billion already pushed due to the supply chain in the quarter, we would characterize this quarter as a major statement on iPhone/Services demand and Cupertino&#39;s ability to navigate a supply chain shortage in almost Teflon-like fashion,&#34; the analyst said.</p><p>Apple CEO <b>Tim Cook</b> noted supply chain improvement for the March quarter, which are &#34;calming words heard around the tech world,&#34; he said.</p><p>With ASPs continuing to be very positive on Pro/Pro Max and roughly 250 million of 975 million iPhones worldwide not upgrading in 3 1/2 years, the focus is on the demand front, Ives said. Supply chain issues are unlikely to crash the iPhone growth story in 2022, he said.</p><p><b>AAPL Price Action:</b>In after-hours trading, Apple shares were rallying 4.4% to $166.15.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-28 08:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><b>Apple, Inc.</b> reported late Thursday with strong quarterly results that &#34;wowed&#34; a Wedbush analyst.</p><p><img src=\"https://static.tigerbbs.com/46f1d5c88a1b989ac1e46cf46560b032\" tg-width=\"660\" tg-height=\"300\" width=\"100%\" height=\"auto\"/></p><p><b>The Apple Analyst:</b>Daniel Ives has an Outperform rating on Apple with a $200 price target.</p><p><b>The Apple Takeaways:</b>Apple&#39;s robust quarter will be the focus of the tech universe, especially as the Street harbored major supply chain and growth fears, heading into the print, Ives said in a note.</p><p>The iPhone was the &#34;star of the show,&#34; as revenues from the product beat the Street estimates and the Services business also exceeded expectations, the analyst said. The beat was across all product categories, except the iPad, he said.</p><p>The bottom-line result of $2.10 and margins were also ahead of expectations, Ives said.</p><p>&#34;Overall, with $6 billion already pushed due to the supply chain in the quarter, we would characterize this quarter as a major statement on iPhone/Services demand and Cupertino&#39;s ability to navigate a supply chain shortage in almost Teflon-like fashion,&#34; the analyst said.</p><p>Apple CEO <b>Tim Cook</b> noted supply chain improvement for the March quarter, which are &#34;calming words heard around the tech world,&#34; he said.</p><p>With ASPs continuing to be very positive on Pro/Pro Max and roughly 250 million of 975 million iPhones worldwide not upgrading in 3 1/2 years, the focus is on the demand front, Ives said. Supply chain issues are unlikely to crash the iPhone growth story in 2022, he said.</p><p><b>AAPL Price Action:</b>In after-hours trading, Apple shares were rallying 4.4% to $166.15.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110430857","content_text":"Apple, Inc. reported late Thursday with strong quarterly results that \"wowed\" a Wedbush analyst.The Apple Analyst:Daniel Ives has an Outperform rating on Apple with a $200 price target.The Apple Takeaways:Apple's robust quarter will be the focus of the tech universe, especially as the Street harbored major supply chain and growth fears, heading into the print, Ives said in a note.The iPhone was the \"star of the show,\" as revenues from the product beat the Street estimates and the Services business also exceeded expectations, the analyst said. The beat was across all product categories, except the iPad, he said.The bottom-line result of $2.10 and margins were also ahead of expectations, Ives said.\"Overall, with $6 billion already pushed due to the supply chain in the quarter, we would characterize this quarter as a major statement on iPhone/Services demand and Cupertino's ability to navigate a supply chain shortage in almost Teflon-like fashion,\" the analyst said.Apple CEO Tim Cook noted supply chain improvement for the March quarter, which are \"calming words heard around the tech world,\" he said.With ASPs continuing to be very positive on Pro/Pro Max and roughly 250 million of 975 million iPhones worldwide not upgrading in 3 1/2 years, the focus is on the demand front, Ives said. Supply chain issues are unlikely to crash the iPhone growth story in 2022, he said.AAPL Price Action:In after-hours trading, Apple shares were rallying 4.4% to $166.15.","news_type":1},"isVote":1,"tweetType":1,"viewCount":390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9007057283,"gmtCreate":1642725378260,"gmtModify":1676533740180,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"Horray!","listText":"Horray!","text":"Horray!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9007057283","repostId":"1134491773","repostType":2,"repost":{"id":"1134491773","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642689793,"share":"https://ttm.financial/m/news/1134491773?lang=&edition=fundamental","pubTime":"2022-01-20 22:43","market":"us","language":"en","title":"Hot Chinese ADRs Gained in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1134491773","media":"Tiger Newspress","summary":"Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.","content":"<html><head></head><body><p>Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.</p><p><img src=\"https://static.tigerbbs.com/96bc8b16c942e17e728eded527960910\" tg-width=\"405\" tg-height=\"588\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot Chinese ADRs Gained in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot Chinese ADRs Gained in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-20 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.</p><p><img src=\"https://static.tigerbbs.com/96bc8b16c942e17e728eded527960910\" tg-width=\"405\" tg-height=\"588\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDD":"拼多多","JD":"京东"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134491773","content_text":"Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002822441,"gmtCreate":1641969751391,"gmtModify":1676533667690,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"🥳","listText":"🥳","text":"🥳","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002822441","repostId":"1169397242","repostType":4,"repost":{"id":"1169397242","pubTimestamp":1641965030,"share":"https://ttm.financial/m/news/1169397242?lang=&edition=fundamental","pubTime":"2022-01-12 13:23","market":"us","language":"en","title":"Why Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1169397242","media":"Benzinga","summary":"Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark","content":"<html><head></head><body><p>Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark <b>Hang Seng Index</b> notably higher.</p><p><b>What’s Moving</b>: Shares of <b>Alibaba Group Holding Limited</b>,<b>BaiduInc.</b>,<b>JD.Com Inc.</b>, <b>Tencent Holdings Inc</b>., <b>Li Auto Inc.</b> and <b>Xpeng Inc.</b>, traded higher in a range of 3% to 9%.</p><p>The Hang Seng Index rebounded opened higher on Wednesday and was up almost 2.0% at the time of writing. The index closed little changed on Tuesday, ending a three-day winning streak.</p><p><b>Why Is It Moving?</b> The Hang Seng Index rose after official data showed that China’s inflation rose slower than expected in December. The data raised hopes of more policy easing as China’s economy continues to struggle with property sector woes and repeated COVID-19 outbreaks.</p><p>China’s consumer price Index (CPI) grew 1.5% year-over-year in December, while the producer price index (PPI) rose 10.3% from a year earlier, as per areport by Reuters, citing the National Bureau of Statistics.</p><p><b>Tesla Inc.’s</b> China sales rose in December and outperformed the industry in terms of year-over-year and sequential growth, it was reported on Tuesday. The <b>Elon Musk</b>-led company’s Chinese rivals —<b>Nio Inc.</b>, XPeng and Li Auto — had also previously reported strong deliveries for December.</p><p>Shares of Chinese companies closed notably higher in U.S. trading on Monday after the major averages in the U.S. ended higher. Federal Reserve Chair <b>Jerome Powell</b> said the central bank would use all of its tools to prevent higher inflation from becoming entrenched.</p><p>Alibaba’s shares closed 3.0% higher, while Nio’s shares ended higher by 3.8%.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 13:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/22/01/25010161/why-alibaba-and-other-tech-stocks-are-shooting-up-in-hong-kong-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark Hang Seng Index notably higher.What’s Moving: Shares of Alibaba Group Holding Limited,BaiduInc.,JD....</p>\n\n<a href=\"https://www.benzinga.com/news/22/01/25010161/why-alibaba-and-other-tech-stocks-are-shooting-up-in-hong-kong-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W"},"source_url":"https://www.benzinga.com/news/22/01/25010161/why-alibaba-and-other-tech-stocks-are-shooting-up-in-hong-kong-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169397242","content_text":"Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark Hang Seng Index notably higher.What’s Moving: Shares of Alibaba Group Holding Limited,BaiduInc.,JD.Com Inc., Tencent Holdings Inc., Li Auto Inc. and Xpeng Inc., traded higher in a range of 3% to 9%.The Hang Seng Index rebounded opened higher on Wednesday and was up almost 2.0% at the time of writing. The index closed little changed on Tuesday, ending a three-day winning streak.Why Is It Moving? The Hang Seng Index rose after official data showed that China’s inflation rose slower than expected in December. The data raised hopes of more policy easing as China’s economy continues to struggle with property sector woes and repeated COVID-19 outbreaks.China’s consumer price Index (CPI) grew 1.5% year-over-year in December, while the producer price index (PPI) rose 10.3% from a year earlier, as per areport by Reuters, citing the National Bureau of Statistics.Tesla Inc.’s China sales rose in December and outperformed the industry in terms of year-over-year and sequential growth, it was reported on Tuesday. The Elon Musk-led company’s Chinese rivals —Nio Inc., XPeng and Li Auto — had also previously reported strong deliveries for December.Shares of Chinese companies closed notably higher in U.S. trading on Monday after the major averages in the U.S. ended higher. Federal Reserve Chair Jerome Powell said the central bank would use all of its tools to prevent higher inflation from becoming entrenched.Alibaba’s shares closed 3.0% higher, while Nio’s shares ended higher by 3.8%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006879908,"gmtCreate":1641695723593,"gmtModify":1676533640723,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"How many doses do we have to take eventually?🤪","listText":"How many doses do we have to take eventually?🤪","text":"How many doses do we have to take eventually?🤪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006879908","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","pubTimestamp":1641612579,"share":"https://ttm.financial/m/news/1134509683?lang=&edition=fundamental","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body><p>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><b>A safe harbor in stormy weather</b></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><b>The antibody market all to itself</b></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","VIR":"Vir Biotechnology, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574671931921507","authorId":"3574671931921507","name":"Wayneqq","avatar":"https://static.tigerbbs.com/05d24be2c05653913e90f51e69cfe2a8","crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3574671931921507","idStr":"3574671931921507"},"content":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots","text":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots","html":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863557941,"gmtCreate":1632407875483,"gmtModify":1676530775733,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/9CI.SI\">$CapitaLandInves(9CI.SI)$</a>Went up for the past few days","listText":"<a href=\"https://laohu8.com/S/9CI.SI\">$CapitaLandInves(9CI.SI)$</a>Went up for the past few days","text":"$CapitaLandInves(9CI.SI)$Went up for the past few days","images":[{"img":"https://static.tigerbbs.com/97150f41d6ac3fb70544cd1131cb3f9f","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863557941","isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":863552125,"gmtCreate":1632407738367,"gmtModify":1676530775660,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>CGS-CIMB keeps 'add' on ThaiBev on attractive valuation.Link below:https://www.theedgesingapore.com/capital/brokers-calls/cgs-cimb-keeps-add-thaibev-attractive-valuation","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>CGS-CIMB keeps 'add' on ThaiBev on attractive valuation.Link below:https://www.theedgesingapore.com/capital/brokers-calls/cgs-cimb-keeps-add-thaibev-attractive-valuation","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$CGS-CIMB keeps 'add' on ThaiBev on attractive valuation.Link below:https://www.theedgesingapore.com/capital/brokers-calls/cgs-cimb-keeps-add-thaibev-attractive-valuation","images":[{"img":"https://static.tigerbbs.com/8789742cb331f1363cd7ad21804169bd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863552125","isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869630433,"gmtCreate":1632277767622,"gmtModify":1676530741756,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/H22.SI\">$HONG LEONG ASIA LTD.(H22.SI)$</a>I am expecting this share to be around $1.","listText":"<a href=\"https://laohu8.com/S/H22.SI\">$HONG LEONG ASIA LTD.(H22.SI)$</a>I am expecting this share to be around $1.","text":"$HONG LEONG ASIA LTD.(H22.SI)$I am expecting this share to be around $1.","images":[{"img":"https://static.tigerbbs.com/ef5ade7f3180f3e0f369e9e2a0d98c1a","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869630433","isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869630635,"gmtCreate":1632277707527,"gmtModify":1676530741757,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Be patience.","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Be patience.","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Be patience.","images":[{"img":"https://static.tigerbbs.com/e609987ca7b55f9120f8751d34eee260","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869630635","isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869917758,"gmtCreate":1632234868374,"gmtModify":1676530731447,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BIDU\">$Baidu(BIDU)$</a>share my position","listText":"<a href=\"https://laohu8.com/S/BIDU\">$Baidu(BIDU)$</a>share my position","text":"$Baidu(BIDU)$share my position","images":[{"img":"https://static.tigerbbs.com/23d0a718bee2e52de6be8dec063a6edf","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869917758","isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869915780,"gmtCreate":1632234784440,"gmtModify":1676530731400,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>share my position","listText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>share my position","text":"$ESR-REIT(J91U.SI)$share my position","images":[{"img":"https://static.tigerbbs.com/be61c552dd36ba40409d0ab320089aa2","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869915780","isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":860100314,"gmtCreate":1632142658338,"gmtModify":1676530709203,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Will you get this stock?","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Will you get this stock?","text":"$Pfizer(PFE)$Will you get this stock?","images":[{"img":"https://static.tigerbbs.com/74f5664b1480413c7d7afd13cc3e6ebc","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860100314","isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":885352973,"gmtCreate":1631758691792,"gmtModify":1676530628047,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/H22.SI\">$HONG LEONG ASIA LTD.(H22.SI)$</a>When is your show time to have the upward trend?&nbsp;","listText":"<a href=\"https://laohu8.com/S/H22.SI\">$HONG LEONG ASIA LTD.(H22.SI)$</a>When is your show time to have the upward trend?&nbsp;","text":"$HONG LEONG ASIA LTD.(H22.SI)$When is your show time to have the upward trend?","images":[{"img":"https://static.tigerbbs.com/c452a2dd14286e119b410a84b619f3c6","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885352973","isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":886723979,"gmtCreate":1631627074191,"gmtModify":1676530593517,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BIDU\">$Baidu(BIDU)$</a>Share my position.","listText":"<a href=\"https://laohu8.com/S/BIDU\">$Baidu(BIDU)$</a>Share my position.","text":"$Baidu(BIDU)$Share my position.","images":[{"img":"https://static.tigerbbs.com/9faec230305ffe7ca46ec78cc6d37eb3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886723979","isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":886729695,"gmtCreate":1631627035417,"gmtModify":1676530593533,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/U96.SI\">$SEMBCORP INDUSTRIES LTD(U96.SI)$</a>Will you buy this share with loss PE? This share is meant for long term.","listText":"<a href=\"https://laohu8.com/S/U96.SI\">$SEMBCORP INDUSTRIES LTD(U96.SI)$</a>Will you buy this share with loss PE? This share is meant for long term.","text":"$SEMBCORP INDUSTRIES LTD(U96.SI)$Will you buy this share with loss PE? This share is meant for long term.","images":[{"img":"https://static.tigerbbs.com/8a2aba2990972b50400753ec41e18cd5","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886729695","isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":888549631,"gmtCreate":1631511240323,"gmtModify":1676530562077,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/U9E.SI\">$CHINA EVERBRIGHT WATER LIMITED(U9E.SI)$</a>what happened to this stock?","listText":"<a href=\"https://laohu8.com/S/U9E.SI\">$CHINA EVERBRIGHT WATER LIMITED(U9E.SI)$</a>what happened to this stock?","text":"$CHINA EVERBRIGHT WATER LIMITED(U9E.SI)$what happened to this stock?","images":[{"img":"https://static.tigerbbs.com/832baf7fe2a9674f0e32026118602858","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888549631","isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":888540756,"gmtCreate":1631511199975,"gmtModify":1676530562043,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Hope to see you in green again.","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Hope to see you in green again.","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Hope to see you in green again.","images":[{"img":"https://static.tigerbbs.com/cbd93cad924794e59437eb6b0c3e099e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888540756","isVote":1,"tweetType":1,"viewCount":116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":883740002,"gmtCreate":1631276692606,"gmtModify":1676530516326,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BIDU\">$Baidu(BIDU)$</a>AI is the next IOT. Please support this stock.","listText":"<a href=\"https://laohu8.com/S/BIDU\">$Baidu(BIDU)$</a>AI is the next IOT. Please support this stock.","text":"$Baidu(BIDU)$AI is the next IOT. Please support this stock.","images":[{"img":"https://static.tigerbbs.com/ff064f2b594fe581b5d48fbee1ff347b","width":"1080","height":"3355"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883740002","isVote":1,"tweetType":1,"viewCount":249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":883751754,"gmtCreate":1631276311678,"gmtModify":1676530516193,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>share my position","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>share my position","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$share my position","images":[{"img":"https://static.tigerbbs.com/b3d82fa4a147650c20185348b0e93bc9","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883751754","isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":835224860,"gmtCreate":1629722593950,"gmtModify":1676530111111,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BIDU\">$Baidu(BIDU)$</a>Today will be up or down leh?","listText":"<a href=\"https://laohu8.com/S/BIDU\">$Baidu(BIDU)$</a>Today will be up or down leh?","text":"$Baidu(BIDU)$Today will be up or down leh?","images":[{"img":"https://static.tigerbbs.com/62386c3bedc2edf85f79a9e71a4a3cf4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":7,"repostSize":0,"link":"https://ttm.financial/post/835224860","isVote":1,"tweetType":1,"viewCount":907,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3570622365838239","authorId":"3570622365838239","name":"N30","avatar":"https://community-static.tradeup.com/news/33bf6a97d91ccaf61eb8245d0322ab01","crmLevel":5,"crmLevelSwitch":1,"idStr":"3570622365838239","authorIdStr":"3570622365838239"},"content":"Probably another quarter ?‍♂️ Fundamentally nothing has changed. Have faith, and stop reading comments by clowns ? or you’ll do dumb things.","text":"Probably another quarter ?‍♂️ Fundamentally nothing has changed. Have faith, and stop reading comments by clowns ? or you’ll do dumb things.","html":"Probably another quarter ?‍♂️ Fundamentally nothing has changed. Have faith, and stop reading comments by clowns ? or you’ll do dumb things."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":175102894,"gmtCreate":1627010805718,"gmtModify":1703482406536,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>When will it up again?","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>When will it up again?","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$When will it up again?","images":[{"img":"https://static.tigerbbs.com/d6006deb183872399581197c4d28ca65","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/175102894","isVote":1,"tweetType":1,"viewCount":222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9006879908,"gmtCreate":1641695723593,"gmtModify":1676533640723,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"How many doses do we have to take eventually?🤪","listText":"How many doses do we have to take eventually?🤪","text":"How many doses do we have to take eventually?🤪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006879908","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","pubTimestamp":1641612579,"share":"https://ttm.financial/m/news/1134509683?lang=&edition=fundamental","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body><p>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><b>A safe harbor in stormy weather</b></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><b>The antibody market all to itself</b></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","VIR":"Vir Biotechnology, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574671931921507","authorId":"3574671931921507","name":"Wayneqq","avatar":"https://static.tigerbbs.com/05d24be2c05653913e90f51e69cfe2a8","crmLevel":5,"crmLevelSwitch":0,"idStr":"3574671931921507","authorIdStr":"3574671931921507"},"content":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots","text":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots","html":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819296896,"gmtCreate":1630071380015,"gmtModify":1676530216268,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>Drop after the rights are issued.","listText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>Drop after the rights are issued.","text":"$ESR-REIT(J91U.SI)$Drop after the rights are issued.","images":[{"img":"https://static.tigerbbs.com/3d02d8a8de98c0d8582d853e6e02f53a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/819296896","isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4089501973615070","authorId":"4089501973615070","name":"Optionspuppy","avatar":"https://static.tigerbbs.com/caf34258aff8afe478620b82647f1199","crmLevel":6,"crmLevelSwitch":1,"idStr":"4089501973615070","authorIdStr":"4089501973615070"},"content":"Its up today like and commejt tjanks","text":"Its up today like and commejt tjanks","html":"Its up today like and commejt tjanks"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":172322153,"gmtCreate":1626938888572,"gmtModify":1703480930470,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"I have already sold off this stock last week. It is dropping slightly.","listText":"I have already sold off this stock last week. It is dropping slightly.","text":"I have already sold off this stock last week. It is dropping slightly.","images":[{"img":"https://static.tigerbbs.com/d0d655d8fcbf499c168065b18e11695e","width":"1080","height":"3120"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/172322153","isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574671931921507","authorId":"3574671931921507","name":"Wayneqq","avatar":"https://static.tigerbbs.com/05d24be2c05653913e90f51e69cfe2a8","crmLevel":5,"crmLevelSwitch":0,"idStr":"3574671931921507","authorIdStr":"3574671931921507"},"content":"You found a better one to establish a position? Do share [Grin]","text":"You found a better one to establish a position? Do share [Grin]","html":"You found a better one to establish a position? Do share [Grin]"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128390842,"gmtCreate":1624500364686,"gmtModify":1703838497287,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CEDU.SI\">$DASIN RETAIL TRUST(CEDU.SI)$</a>A&nbsp;potential stock to buy.","listText":"<a href=\"https://laohu8.com/S/CEDU.SI\">$DASIN RETAIL TRUST(CEDU.SI)$</a>A&nbsp;potential stock to buy.","text":"$DASIN RETAIL TRUST(CEDU.SI)$A potential stock to buy.","images":[{"img":"https://static.tigerbbs.com/c69689c29dbd5ad49b4c8a4022f72352","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/128390842","isVote":1,"tweetType":1,"viewCount":369,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","crmLevel":4,"crmLevelSwitch":1,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"content":"ya i just started buying... very undervalued... think now the roadblock is the refinancing due in july 2021... once that is secured... it will fly back","text":"ya i just started buying... very undervalued... think now the roadblock is the refinancing due in july 2021... once that is secured... it will fly back","html":"ya i just started buying... very undervalued... think now the roadblock is the refinancing due in july 2021... once that is secured... it will fly back"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":880944844,"gmtCreate":1631014714588,"gmtModify":1676530442414,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/K2LU.SI\">$CACHE LOGISTICS TRUST(K2LU.SI)$</a>This is a very gd stock with upwards trend.","listText":"<a href=\"https://laohu8.com/S/K2LU.SI\">$CACHE LOGISTICS TRUST(K2LU.SI)$</a>This is a very gd stock with upwards trend.","text":"$CACHE LOGISTICS TRUST(K2LU.SI)$This is a very gd stock with upwards trend.","images":[{"img":"https://static.tigerbbs.com/2f6cbc482052252e69b82e63e7b704c9","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/880944844","isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":149245846,"gmtCreate":1625732697985,"gmtModify":1703747340496,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIS\">$Walt Disney(DIS)$</a>when should i sell away this stock?","listText":"<a href=\"https://laohu8.com/S/DIS\">$Walt Disney(DIS)$</a>when should i sell away this stock?","text":"$Walt Disney(DIS)$when should i sell away this stock?","images":[{"img":"https://static.tigerbbs.com/d482a23c782cb58cb5e99865fb43d8cd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":1,"link":"https://ttm.financial/post/149245846","isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574671931921507","authorId":"3574671931921507","name":"Wayneqq","avatar":"https://static.tigerbbs.com/05d24be2c05653913e90f51e69cfe2a8","crmLevel":5,"crmLevelSwitch":0,"idStr":"3574671931921507","authorIdStr":"3574671931921507"},"content":"When you have identified a better investment opportunity that will grow your money faster than disney","text":"When you have identified a better investment opportunity that will grow your money faster than disney","html":"When you have identified a better investment opportunity that will grow your money faster than disney"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":896161969,"gmtCreate":1628562070951,"gmtModify":1703508155226,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"Dasin Retail Trust : The retail property trust reported on Monday a 55.2 per cent increase in DPU to 2.98 Singapore cents for its first half ended June 30, from 1.92 cents a year ago.","listText":"Dasin Retail Trust : The retail property trust reported on Monday a 55.2 per cent increase in DPU to 2.98 Singapore cents for its first half ended June 30, from 1.92 cents a year ago.","text":"Dasin Retail Trust : The retail property trust reported on Monday a 55.2 per cent increase in DPU to 2.98 Singapore cents for its first half ended June 30, from 1.92 cents a year ago.","images":[{"img":"https://static.tigerbbs.com/675c0972039f323cfb1328340700551e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/896161969","isVote":1,"tweetType":1,"viewCount":860,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578630064980119","authorId":"3578630064980119","name":"BGTAN","avatar":"https://static.tigerbbs.com/8ca7305b1f6bd1d4dd9abf3c54e6fbdb","crmLevel":3,"crmLevelSwitch":1,"idStr":"3578630064980119","authorIdStr":"3578630064980119"},"content":"Got money to pay divide, but can't afford to clear short term loan [Glance]","text":"Got money to pay divide, but can't afford to clear short term loan [Glance]","html":"Got money to pay divide, but can't afford to clear short term loan [Glance]"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148672021,"gmtCreate":1625974939963,"gmtModify":1703751499340,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Expect some panick sell when the market is open tmr due to bangkok and 9 provinces in lockdown from 12 Jul 21.","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Expect some panick sell when the market is open tmr due to bangkok and 9 provinces in lockdown from 12 Jul 21.","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Expect some panick sell when the market is open tmr due to bangkok and 9 provinces in lockdown from 12 Jul 21.","images":[{"img":"https://static.tigerbbs.com/82118f94e12d758f54c1860ea7bf93f9","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/148672021","isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Thanks for the tip. Time to buy more?","text":"Thanks for the tip. Time to buy more?","html":"Thanks for the tip. Time to buy more?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9059990241,"gmtCreate":1654272962983,"gmtModify":1676535423684,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Just bought abit of this share today! Huat ah!","listText":"<a href=\"https://ttm.financial/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Just bought abit of this share today! Huat ah!","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Just bought abit of this share today! Huat ah!","images":[{"img":"https://community-static.tradeup.com/news/be2d3c77e2bf92d52c4e7bdab6f2bafe","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9059990241","isVote":1,"tweetType":1,"viewCount":342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":802503992,"gmtCreate":1627785562416,"gmtModify":1703495825086,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"Is it the right time to get more SIA shares?&nbsp;","listText":"Is it the right time to get more SIA shares?&nbsp;","text":"Is it the right time to get more SIA shares?","images":[{"img":"https://static.tigerbbs.com/20f8111e52b7fd70d6c050c2b09b834e","width":"1080","height":"3120"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/802503992","isVote":1,"tweetType":1,"viewCount":28,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":179124446,"gmtCreate":1626495253285,"gmtModify":1703761140530,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>The share price&nbsp;is fluctating&nbsp;between 0.665 to 0.67 cents. Hope to have gd news soon.","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>The share price&nbsp;is fluctating&nbsp;between 0.665 to 0.67 cents. Hope to have gd news soon.","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$The share price is fluctating between 0.665 to 0.67 cents. Hope to have gd news soon.","images":[{"img":"https://static.tigerbbs.com/69b4c8ca96571227a068684c3cd59fa3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/179124446","isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9051023287,"gmtCreate":1654611383749,"gmtModify":1676535477923,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"Go go go!","listText":"Go go go!","text":"Go go go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9051023287","repostId":"1128523151","repostType":2,"repost":{"id":"1128523151","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1654609740,"share":"https://ttm.financial/m/news/1128523151?lang=&edition=fundamental","pubTime":"2022-06-07 21:49","market":"us","language":"en","title":"Some Hot Chinese ADRs Gained in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1128523151","media":"Tiger Newspress","summary":"Some Hot Chinese ADRs Gained in Morning Trading.Alibaba, Pinduoduo, iQIYI, DiDi Global, Baidu, JD.co","content":"<html><head></head><body><p>Some Hot Chinese ADRs Gained in Morning Trading.</p><p><a href=\"https://laohu8.com/S/BABA\">Alibaba</a>, <a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>, iQIYI, DiDi Global, <a href=\"https://laohu8.com/S/BIDU\">Baidu</a>, <a href=\"https://laohu8.com/S/JD\">JD.com</a>, Bilibili, and NIO climbed between 1% and 7%.</p><p><img src=\"https://static.tigerbbs.com/46cf305cfd9d3f235469219b4a219ad7\" tg-width=\"445\" tg-height=\"647\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Hot Chinese ADRs Gained in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Hot Chinese ADRs Gained in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-06-07 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some Hot Chinese ADRs Gained in Morning Trading.</p><p><a href=\"https://laohu8.com/S/BABA\">Alibaba</a>, <a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>, iQIYI, DiDi Global, <a href=\"https://laohu8.com/S/BIDU\">Baidu</a>, <a href=\"https://laohu8.com/S/JD\">JD.com</a>, Bilibili, and NIO climbed between 1% and 7%.</p><p><img src=\"https://static.tigerbbs.com/46cf305cfd9d3f235469219b4a219ad7\" tg-width=\"445\" tg-height=\"647\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","PDD":"拼多多","BILI":"哔哩哔哩","BIDU":"百度","BK4577":"网络游戏","BK4579":"人工智能","BK4552":"Archegos爆仓风波概念","BK4122":"互联网与直销零售","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4502":"阿里概念","BK1521":"挪威政府全球养老基金持仓","BK4510":"在线教育","BK1586":"云计算","BK1095":"互动媒体与服务","09888":"百度集团-SW","BK1142":"互联网与直销零售","BK1591":"就地过年概念","09988":"阿里巴巴-W","09618":"京东集团-SW","JD":"京东"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128523151","content_text":"Some Hot Chinese ADRs Gained in Morning Trading.Alibaba, Pinduoduo, iQIYI, DiDi Global, Baidu, JD.com, Bilibili, and NIO climbed between 1% and 7%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816663923,"gmtCreate":1630497230062,"gmtModify":1676530320017,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>ESR-Reit is pivoting towards logistics assets. Twelve out of 58 properties ESR-Reit holds interests in are logistic properties. The Reit has also completed its maiden overseas acquisition in Australia and has plans to raise the gross floor area at two of its properties through asset enhancement initiativesLink belowhttps://www.businesstimes.com.sg/stocks/brokers-take-esr-reit-ara-logos-lendlease-global-cromwell-e-reit-are-uobkhs-top-contenders","listText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>ESR-Reit is pivoting towards logistics assets. Twelve out of 58 properties ESR-Reit holds interests in are logistic properties. The Reit has also completed its maiden overseas acquisition in Australia and has plans to raise the gross floor area at two of its properties through asset enhancement initiativesLink belowhttps://www.businesstimes.com.sg/stocks/brokers-take-esr-reit-ara-logos-lendlease-global-cromwell-e-reit-are-uobkhs-top-contenders","text":"$ESR-REIT(J91U.SI)$ESR-Reit is pivoting towards logistics assets. Twelve out of 58 properties ESR-Reit holds interests in are logistic properties. The Reit has also completed its maiden overseas acquisition in Australia and has plans to raise the gross floor area at two of its properties through asset enhancement initiativesLink belowhttps://www.businesstimes.com.sg/stocks/brokers-take-esr-reit-ara-logos-lendlease-global-cromwell-e-reit-are-uobkhs-top-contenders","images":[{"img":"https://static.tigerbbs.com/0e11744b4879857bebeb0be803dfe5ef","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816663923","isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":895013110,"gmtCreate":1628693661730,"gmtModify":1676529824602,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>horray!","listText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>horray!","text":"$ESR-REIT(J91U.SI)$horray!","images":[{"img":"https://static.tigerbbs.com/3bea168f08d276b9bb63562bc96c2c0b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/895013110","isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":804442192,"gmtCreate":1627976073416,"gmtModify":1703498939854,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>share my position","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>share my position","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$share my position","images":[{"img":"https://static.tigerbbs.com/62e795e1718046cb2a9b1a0245183972","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804442192","isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":808390729,"gmtCreate":1627554850961,"gmtModify":1703492268615,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>Horray! Finally see green..","listText":"<a href=\"https://laohu8.com/S/J91U.SI\">$ESR-REIT(J91U.SI)$</a>Horray! Finally see green..","text":"$ESR-REIT(J91U.SI)$Horray! Finally see green..","images":[{"img":"https://static.tigerbbs.com/b8e7ad63c553b88d365e8157272ad181","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/808390729","isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":808974405,"gmtCreate":1627554299607,"gmtModify":1703492253358,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"Noted.","listText":"Noted.","text":"Noted.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/808974405","repostId":"2155990524","repostType":4,"repost":{"id":"2155990524","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627549354,"share":"https://ttm.financial/m/news/2155990524?lang=&edition=fundamental","pubTime":"2021-07-29 17:02","market":"us","language":"en","title":"7 Stocks To Watch For July 29, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2155990524","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\tWall Street expects  Mastercard Inc (NYSE: MA) to report quarterly earnings at $1.72 per share on revenue of $4.34 billion before the opening bell. Mastercard shares fell 0.2% to $382.88 in after-hours trading.\n","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects <b>Mastercard Inc</b> (NYSE:MA) to report quarterly earnings at $1.72 per share on revenue of $4.34 billion before the opening bell. Mastercard shares rose 0.2% to $384.23 in premarket trading.</li>\n <li><b>Ford Motor Company</b> (NYSE:F) reported a surprise profit for the second quarter, while sales also exceeded market estimates. The company also raised its profit guidance for the year. Ford shares gained 3.8% to $14.38 in premarket trading.</li>\n <li>Analysts expect <b>Merck &amp; Co., Inc.</b> (NYSE:MRK) to post quarterly earnings at $1.44 per share on revenue of $11.54 billion before the opening bell. Merck shares rose 0.2% to $78.46 in premarket trading.</li>\n <li><b><a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc</b> (NASDAQ:FB) reported better-than-expected earnings for its second quarter. The company saw its daily active users grow 7% year-over-year to 1.91 billion in the quarter. Monthly active users increased 7% to 2.9 billion. Facebook said its third- and fourth-quarter revenue growth rates could decelerate “significantly” due to going against tough comp periods from the prior year. Facebook shares, however, fell 3.6% to $359.98 in premarket trading.</li>\n</ul>\n<ul>\n <li>Analysts are expecting <b>AstraZeneca plc</b> (NASDAQ:AZN) to have earned $0.43 per share on revenue of $7.36 billion for the latest quarter. The company will release earnings before the markets open. AstraZeneca shares rose 1.8% to $57.84 in premarket trading.</li>\n <li><b>Paypal Holdings Inc</b> (NASDAQ:PYPL) posted upbeat earnings for its second quarter, but issued weak profit forecast for the current quarter. Paypal shares dropped 5% to $286.80 in premarket trading.</li>\n <li>Analysts expect <b>Comcast Corporation</b> (NASDAQ:CMCSA) to report quarterly earnings at $0.66 per share on revenue of $27.16 billion before the opening bell. Comcast shares fell 0.8% to $57.52 in premarket trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Stocks To Watch For July 29, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Stocks To Watch For July 29, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-29 17:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects <b>Mastercard Inc</b> (NYSE:MA) to report quarterly earnings at $1.72 per share on revenue of $4.34 billion before the opening bell. Mastercard shares rose 0.2% to $384.23 in premarket trading.</li>\n <li><b>Ford Motor Company</b> (NYSE:F) reported a surprise profit for the second quarter, while sales also exceeded market estimates. The company also raised its profit guidance for the year. Ford shares gained 3.8% to $14.38 in premarket trading.</li>\n <li>Analysts expect <b>Merck &amp; Co., Inc.</b> (NYSE:MRK) to post quarterly earnings at $1.44 per share on revenue of $11.54 billion before the opening bell. Merck shares rose 0.2% to $78.46 in premarket trading.</li>\n <li><b><a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc</b> (NASDAQ:FB) reported better-than-expected earnings for its second quarter. The company saw its daily active users grow 7% year-over-year to 1.91 billion in the quarter. Monthly active users increased 7% to 2.9 billion. Facebook said its third- and fourth-quarter revenue growth rates could decelerate “significantly” due to going against tough comp periods from the prior year. Facebook shares, however, fell 3.6% to $359.98 in premarket trading.</li>\n</ul>\n<ul>\n <li>Analysts are expecting <b>AstraZeneca plc</b> (NASDAQ:AZN) to have earned $0.43 per share on revenue of $7.36 billion for the latest quarter. The company will release earnings before the markets open. AstraZeneca shares rose 1.8% to $57.84 in premarket trading.</li>\n <li><b>Paypal Holdings Inc</b> (NASDAQ:PYPL) posted upbeat earnings for its second quarter, but issued weak profit forecast for the current quarter. Paypal shares dropped 5% to $286.80 in premarket trading.</li>\n <li>Analysts expect <b>Comcast Corporation</b> (NASDAQ:CMCSA) to report quarterly earnings at $0.66 per share on revenue of $27.16 billion before the opening bell. Comcast shares fell 0.8% to $57.52 in premarket trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","MA":"万事达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155990524","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Mastercard Inc (NYSE:MA) to report quarterly earnings at $1.72 per share on revenue of $4.34 billion before the opening bell. Mastercard shares rose 0.2% to $384.23 in premarket trading.\nFord Motor Company (NYSE:F) reported a surprise profit for the second quarter, while sales also exceeded market estimates. The company also raised its profit guidance for the year. Ford shares gained 3.8% to $14.38 in premarket trading.\nAnalysts expect Merck & Co., Inc. (NYSE:MRK) to post quarterly earnings at $1.44 per share on revenue of $11.54 billion before the opening bell. Merck shares rose 0.2% to $78.46 in premarket trading.\nFacebook Inc (NASDAQ:FB) reported better-than-expected earnings for its second quarter. The company saw its daily active users grow 7% year-over-year to 1.91 billion in the quarter. Monthly active users increased 7% to 2.9 billion. Facebook said its third- and fourth-quarter revenue growth rates could decelerate “significantly” due to going against tough comp periods from the prior year. Facebook shares, however, fell 3.6% to $359.98 in premarket trading.\n\n\nAnalysts are expecting AstraZeneca plc (NASDAQ:AZN) to have earned $0.43 per share on revenue of $7.36 billion for the latest quarter. The company will release earnings before the markets open. AstraZeneca shares rose 1.8% to $57.84 in premarket trading.\nPaypal Holdings Inc (NASDAQ:PYPL) posted upbeat earnings for its second quarter, but issued weak profit forecast for the current quarter. Paypal shares dropped 5% to $286.80 in premarket trading.\nAnalysts expect Comcast Corporation (NASDAQ:CMCSA) to report quarterly earnings at $0.66 per share on revenue of $27.16 billion before the opening bell. Comcast shares fell 0.8% to $57.52 in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148201870,"gmtCreate":1625975415490,"gmtModify":1703751511979,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581117504935343","authorIdStr":"3581117504935343"},"themes":[],"htmlText":"Is this the right time to get this stock?","listText":"Is this the right time to get this stock?","text":"Is this the right time to get this stock?","images":[{"img":"https://static.tigerbbs.com/a88a50e7fa46f935f342719bc6c7bae6","width":"1080","height":"3071"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/148201870","isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}